Amylocaine

DB09088ApprovedWithdrawnSmall molecule

Amylocaine is a local and topical anaesthetic agent. Despite the introduction of using cocaine injections for regional anesthesia in 1884, non-addictive substitutes were sought after immediately.

Mechanism: In particular, amylocaine, much like other local anesthetics, bind and blockade voltage gated sodium channels located in the excitable membranes of various sensory receptors. Once blocked, the influx of sodium across the channels and membrane is inhibited. Because the influx of sodium is necessary to facilitate neuronal action potentials and signal conduction across sensory receptor membranes, the influx inhibition subsequently prevents the body reactions that would normally result from the neuronal signals.
Curator reviewed · 3 references
Primary indication: The most common indication for the usage of amylocaine was spinal anesthesia.Curator reviewed · 4 structured indications
Formula / weight: C₁₄H₂₁NO₂ · 235.327 g/mol (avg)
First approval: Canada, 1945
Also known as: Stovaine

Resolves to

Compound

UNIIQRW683O56TCAS644-26-8ChEMBLCHEMBL1740065ChEBI34981PubChem10767KEGGD07454

Clinical / RWD

RxNorm40660

Structure

InChIKeyFDMBBCOBEAVDAO-UHFFFAOYSA-NSMILESCCC(C)(CN(C)C)OC(=O)C1=CC=CC=C1

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Structured indicationsCondition, population, route and combination as fields, not prose

13Marketed productsAcross 3 countries and 9 labellers

6+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Amylocaine, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account